US 12,378,217 B2
Process for the preparation of lasmiditan
Shekhar Bhaskar Bhirud, Mumbai (IN); Samir Naik, Thane (IN); Shafakat Ali Nasir Ali, Thane (IN); Pramod Vitthal Patil, Panvel (IN); Deepak Baviskar, Mumbai (IN); Mahendra Ramesh Patil, Jalgaon (IN); and Venkata Raghavendra Acharyulu Palle, Pune (IN)
Assigned to Alivus Life Sciences Limited, Solapur (IN)
Appl. No. 17/795,641
Filed by Alivus Life Sciences Limited, Solapur (IN)
PCT Filed Jan. 27, 2021, PCT No. PCT/IB2021/050603
§ 371(c)(1), (2) Date Jul. 27, 2022,
PCT Pub. No. WO2021/152462, PCT Pub. Date Aug. 5, 2021.
Claims priority of application No. 202021004381 (IN), filed on Jan. 31, 2020.
Prior Publication US 2023/0095474 A1, Mar. 30, 2023
Int. Cl. C07D 401/06 (2006.01); C07D 213/81 (2006.01)
CPC C07D 401/06 (2013.01) [C07D 213/81 (2013.01)] 11 Claims
 
1. A process for lasmiditan, a compound of formula I, or pharmaceutically acceptable salts thereof,

OG Complex Work Unit Chemistry
the process comprising:
(a) reacting a compound of formula III with a compound of formula IIA,

OG Complex Work Unit Chemistry
wherein R is MgX, Li, ZnX, or Sn (C1-C6 alkyl)3; X is selected from the group consisting of Br, Cl, and I; to obtain lasmiditan, the compound of formula I; and
(b) optionally, converting lasmiditan, the compound of formula I, to a pharmaceutically acceptable salt.